Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 2
Encontrada(s) 1 página(s)

Academica-e. Repositorio Institucional de la Universidad Pública de Navarra
Publicación Artículo científico (JournalArticle)

Androgen receptor and fatty acid oxidation cooperate in ferroptosis evasion in BRAFi resistant melanoma

  • Redondo Muñoz, Marta
  • Caballé-Mestres, Adrià
  • Reisz, Julie A.
  • Valero-Leria, Ane
  • Olías Arjona, Ana
  • Aldaz Donamaría, Paula
  • D´Alessandro, Angelo
  • Wellbrock, Claudia
  • Arozarena Martinicorena, Imanol
Melanoma accounts for over 85% of all skin cancer deaths. Current therapies including drugs targeting BRAF and MEK significantly improve the prognosis of metastatic melanoma patients, yet innate or acquired resistance challenges long-term responses. We have shown previously that fatty acid beta-oxidation (FAO) is up-regulated during the acquisition of BRAF-inhibitor (BRAFi) resistance and that the FDA approved drug ranolazine, by targeting FAO attenuates the development of acquired resistance. However, how ranolazine-induced metabolic rewiring increases cell death is unclear. Here we identify ranolazine as a ferroptosis inducer in BRAFi-resistant melanoma, in which FAO serves as a ferroptosis surveillance mechanism. Accordingly, in progressed tumours of BRAFi treated patients up-regulation of FAO regulators correlates with increased expression of ferroptosis markers. BRAFi resistant cells are heavily poised for execution of ferroptosis; they display reduced glutathione levels, higher levels of long-chain polyunsaturated fatty acid (PUFA) membrane-incorporation, and increased membrane-resident phospholipid oxidation, all of which is amplified by ranolazine. Counteracting ranolazine action is MBOAT1/2 mediated phospholipid remodelling, which initiates reduced PUFA membrane-incorporation as ferroptosis surveillance mechanism. We show that the androgen receptor (AR), which is a determinant of BRAFi resistance, controls MBOAT1/2 expression, thereby contributing to ferroptosis resistance. In BRAFi resistant tumours and cell lines, we confirm AR upregulation predominantly in the MITFlow/AXLhigh undifferentiated/neural-crest like state, but it also occurs in the MITFhigh/AXLlow differentiated melanocytic state. The AR antagonist enzalutamide sensitises AR expressing melanoma cells to RSL3 and erastin independent of phenotype state, but in FAOhigh BRAFi relapsed tumours AR up-regulation correlates with the undifferentiated/neural-crest like (UD/NC) state, and enzalutamide synergises with ranolazine in ferroptosis-induction in UD/NC cells. Thus, therapeutically combining ranolazine with the AR inhibitor enzalutamide to induce ferroptosis can circumvent dedifferentiation related BRAFi resistance and could increase therapeutic activity and long-term efficacy., I.A. and P.A. acknowledge funding from the Ministry of Economy and Competitiveness (Institute of Health Carlos III-ISCIII; refs. PI19/00645 to I.A., PI16-01911 to I.A., CPII20/00011 to I.A., CD21/00137 to P.A. I.A. and A.V.L are also funded by Departamento de Salud del Gobierno de Navarra, Spain (refs. G°Na 71/17 and GN2024-54). I.A. and M.R.M. acknowledge funding from The Spanish Association against Cancer (AECC; PRYES223349AROZ). M.R.M. was funded by a PhD studentship from the Department of Industry of the Government of Navarra, Spain, by the Grupo Español Multidisciplinar de Melanoma and the Asociación Española Contra el Cáncer. P.A. was funded by a Sara Borrell contract from ISC-III. The University of Colorado School of Medicine Metabolomics Core is supported in part by the University of Colorado Cancer Centre award from the National Cancer Institute P30CA046934.
Academica-e. Repositorio Institucional de la Universidad Pública de Navarra
Publicación Artículo científico (JournalArticle)

The regulators of peroxisomal acyl-carnitine shuttle CROT and CRAT promote metastasis in melanoma

  • Lasheras Otero, Irene
  • Feliu, Iker
  • Maíllo Ruiz de Infante, Alberto
  • Moreno, Haritz
  • Redondo Muñoz, Marta
  • Aldaz Donamaría, Paula
  • Bocanegra Gondán, Ana Isabel
  • Olías Arjona, Ana
  • Lecanda, Fernando
  • Fernández Irigoyen, Joaquín
  • Santamaría Martínez, Enrique
  • Larráyoz, Ignacio M.
  • Gómez-Cabrero, David
  • Wellbrock, Claudia
  • Vicent, Silvestre
  • Arozarena Martinicorena, Imanol
Circulating tumor cells are the key link between a primary tumor and distant metastases, but once in the bloodstream, loss of adhesion induces cell death. To identify the mechanisms relevant for melanoma circulating tumor cell survival, we performed RNA sequencing and discovered that detached melanoma cells and isolated melanoma circulating tumor cells rewire lipid metabolism by upregulating fatty acid (FA) transport and FA betaoxidation‒related genes. In patients with melanoma, high expression of FA transporters and FA beta-oxidation enzymes significantly correlates with reduced progression-free and overall survival. Among the highest expressed regulators in melanoma circulating tumor cells were the carnitine transferases carnitine O-octanoyltransferase and carnitine acetyltransferase, which control the shuttle of peroxisome-derived medium-chain FAs toward mitochondria to fuel mitochondrial FA beta-oxidation. Knockdown of carnitine O-octanoyltransferase or carnitine acetyltransferase and short-term treatment with peroxisomal or mitochondrial FA beta-oxidation inhibitors thioridazine or ranolazine suppressed melanoma metastasis in mice. Carnitine O-octanoyltransferase and carnitine acetyltransferase depletion could be rescued by medium-chain FA supplementation, indicating that the peroxisomal supply of FAs is crucial for the survival of nonadherent melanoma cells. Our study identifies targeting the FA-based cross-talk between peroxisomes and mitochondria as a potential therapeutic opportunity to challenge melanoma progression. Moreover, the discovery of the antimetastatic activity of the Food and Drug Administration‒approved drug ranolazine carries translational potential., This work was funded by the Instituto de Salud Carlos III-FEDER through PI16-01911 and PI19/00645 to IA. IA and IML acknowledge support through Miguel Servet II fellowships (CPII20/00011 and CPII20/00029). The Health Department of the Government of Navarra, Spain funded work through reference GºNa 71/17. SV is funded by FEDER/Ministerio de Ciencia, Innovación y Universidades - Agencia Estatal de Investigación (PID2020-116344-RB-100) and by Foundation Spanish Association Against Cancer (PROYE20029VICE). ILO is funded through a Navarrabiomed PhD studentship and the Grupo Español Multidisciplinar de Melanoma (reference Beca_GEM). FL was funded by the Cancer Research Thematic Network of the Instituto de Salud Carlos III (RTICC RD12/0036/0066, SAF2015-71606R, RTI2018-094507-B-100) financed by MCIN/AEI/10.13039/501100011033 and by FEDER. FL was also funded by the la Caixa Foundation, Caja Navarra Foundation, and the Foundation AECC. PA is a recipient of a Sara Borrell postdoctoral fellowship from the Instituto de Salud Carlos III (CD21/00137).